FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2274739384> ?p ?o ?g. }

• W2274739384 abstract "Abstract Background The plasma cell malignancy multiple myeloma is usually incurable, partly because the bone marrow niche provides a protective microenvironment for quiescent tumour cells. We hypothesised that bone morphogenetic protein (BMP) signalling, a crucial regulator of cell differentiation in bone marrow, would be altered by multiple myeloma and that pharmacological interventions that manipulate BMP activity have potential to alter disease progression. Methods In vitro, we used human and mouse cell lines and mouse primary stromal cells to test the interaction of BMP signalling with niche and tumour components. In vivo, we used the C57BL/KaLwRij mouse myeloma model to test the effect of BMP signalling disruption with a small molecule LDN-193189 (LDN) on disease progression (as measured by paraprotein and tumour cell number), bone lysis (micro-CT imaging of femoral metaphysis), and anaemia (haemoglobin and production of hepcidin). Findings Tumour BMP signalling activity was increased 10 fold when myeloma cells were cultured with bone marrow stromal cells, but this effect was abrogated by BMP signalling inhibitor LDN. Expression of RANKL, a major mediator of myeloma-induced bone lysis, was reduced 1·6 fold by LDN in stromal cells from myeloma-bearing mice (p=0·03). Consistent with this, in vivo, LDN improved bone volume significantly in myeloma-bearing mice (total femoral bone to tissue volume ratio 36·2 vehicle group, 38·8 LDN group, n=10; p=0·015). LDN also altered the niche-preference (endosteal vs central marrow) of tumour cells to favour the endosteal niche, reported to house the quiescent stem fraction of a multiple myeloma clone (ratio of endosteal to central marrow myeloma cells 0·23 vehicle group, 0·37 LDN group, n=8; p=0·034). Serum hepcidin correlated with disease burden ( r 2 =0·55 p=0·03), which was partly reversed by LDN. Interpretation Our findings show that BMP inhibition improves bone disease in multiple myeloma, possibly by reducing RANKL levels. RANKL inhibitors are effective in multiple myeloma bone disease, so there is potential for therapeutic benefit to BMP inhibition in this context. The additional benefit of hepcidin reduction could alleviate inflammatory anaemia associated with multiple myeloma. However, the LDN-induced alteration of niche preferences by tumour cells might imply changes to stem-cell quiescence, which is now being investigated. Funding Wellcome Trust Research Training Fellowship." @default.
• W2274739384 created "2016-06-24" @default.
• W2274739384 creator A5005030503 @default.
• W2274739384 creator A5013592801 @default.
• W2274739384 creator A5014737228 @default.
• W2274739384 creator A5027450644 @default.
• W2274739384 creator A5034047848 @default.
• W2274739384 creator A5034606078 @default.
• W2274739384 creator A5044237653 @default.
• W2274739384 creator A5048100317 @default.
• W2274739384 creator A5064715231 @default.
• W2274739384 creator A5072918409 @default.
• W2274739384 creator A5083463594 @default.
• W2274739384 date "2016-02-01" @default.
• W2274739384 modified "2023-09-26" @default.
• W2274739384 title "Role of bone morphogenetic protein signalling in bone destruction and niche maintenance in a mouse model of multiple myeloma" @default.
• W2274739384 doi "https://doi.org/10.1016/s0140-6736(16)00434-7" @default.
• W2274739384 hasPublicationYear "2016" @default.
• W2274739384 type Work @default.
• W2274739384 sameAs 2274739384 @default.
• W2274739384 citedByCount "0" @default.
• W2274739384 crossrefType "journal-article" @default.
• W2274739384 hasAuthorship W2274739384A5005030503 @default.
• W2274739384 hasAuthorship W2274739384A5013592801 @default.
• W2274739384 hasAuthorship W2274739384A5014737228 @default.
• W2274739384 hasAuthorship W2274739384A5027450644 @default.
• W2274739384 hasAuthorship W2274739384A5034047848 @default.
• W2274739384 hasAuthorship W2274739384A5034606078 @default.
• W2274739384 hasAuthorship W2274739384A5044237653 @default.
• W2274739384 hasAuthorship W2274739384A5048100317 @default.
• W2274739384 hasAuthorship W2274739384A5064715231 @default.
• W2274739384 hasAuthorship W2274739384A5072918409 @default.
• W2274739384 hasAuthorship W2274739384A5083463594 @default.
• W2274739384 hasBestOaLocation W22747393841 @default.
• W2274739384 hasConcept C104317684 @default.
• W2274739384 hasConcept C126322002 @default.
• W2274739384 hasConcept C142724271 @default.
• W2274739384 hasConcept C16930146 @default.
• W2274739384 hasConcept C170493617 @default.
• W2274739384 hasConcept C202751555 @default.
• W2274739384 hasConcept C203014093 @default.
• W2274739384 hasConcept C2776364478 @default.
• W2274739384 hasConcept C2779428903 @default.
• W2274739384 hasConcept C2780007613 @default.
• W2274739384 hasConcept C28328180 @default.
• W2274739384 hasConcept C30352789 @default.
• W2274739384 hasConcept C31507581 @default.
• W2274739384 hasConcept C502942594 @default.
• W2274739384 hasConcept C55493867 @default.
• W2274739384 hasConcept C71924100 @default.
• W2274739384 hasConcept C86803240 @default.
• W2274739384 hasConcept C88045685 @default.
• W2274739384 hasConcept C95444343 @default.
• W2274739384 hasConceptScore W2274739384C104317684 @default.
• W2274739384 hasConceptScore W2274739384C126322002 @default.
• W2274739384 hasConceptScore W2274739384C142724271 @default.
• W2274739384 hasConceptScore W2274739384C16930146 @default.
• W2274739384 hasConceptScore W2274739384C170493617 @default.
• W2274739384 hasConceptScore W2274739384C202751555 @default.
• W2274739384 hasConceptScore W2274739384C203014093 @default.
• W2274739384 hasConceptScore W2274739384C2776364478 @default.
• W2274739384 hasConceptScore W2274739384C2779428903 @default.
• W2274739384 hasConceptScore W2274739384C2780007613 @default.
• W2274739384 hasConceptScore W2274739384C28328180 @default.
• W2274739384 hasConceptScore W2274739384C30352789 @default.
• W2274739384 hasConceptScore W2274739384C31507581 @default.
• W2274739384 hasConceptScore W2274739384C502942594 @default.
• W2274739384 hasConceptScore W2274739384C55493867 @default.
• W2274739384 hasConceptScore W2274739384C71924100 @default.
• W2274739384 hasConceptScore W2274739384C86803240 @default.
• W2274739384 hasConceptScore W2274739384C88045685 @default.
• W2274739384 hasConceptScore W2274739384C95444343 @default.
• W2274739384 hasLocation W22747393841 @default.
• W2274739384 hasOpenAccess W2274739384 @default.
• W2274739384 hasPrimaryLocation W22747393841 @default.
• W2274739384 hasRelatedWork W1991753648 @default.
• W2274739384 hasRelatedWork W2018837729 @default.
• W2274739384 hasRelatedWork W2037992078 @default.
• W2274739384 hasRelatedWork W2038063884 @default.
• W2274739384 hasRelatedWork W2138808490 @default.
• W2274739384 hasRelatedWork W2263267431 @default.
• W2274739384 hasRelatedWork W2396393193 @default.
• W2274739384 hasRelatedWork W2397539469 @default.
• W2274739384 hasRelatedWork W2407549070 @default.
• W2274739384 hasRelatedWork W2408784386 @default.
• W2274739384 hasRelatedWork W2532923154 @default.
• W2274739384 hasRelatedWork W2551430673 @default.
• W2274739384 hasRelatedWork W2555412724 @default.
• W2274739384 hasRelatedWork W2594527300 @default.
• W2274739384 hasRelatedWork W2772258348 @default.
• W2274739384 hasRelatedWork W2785043284 @default.
• W2274739384 hasRelatedWork W2804795669 @default.
• W2274739384 hasRelatedWork W2982179535 @default.
• W2274739384 hasRelatedWork W2994853782 @default.
• W2274739384 hasRelatedWork W2999983887 @default.
• W2274739384 isParatext "false" @default.
• W2274739384 isRetracted "false" @default.
• W2274739384 magId "2274739384" @default.
• W2274739384 workType "article" @default.